Dexamethasone intravitreal implant (Aerie Pharmaceuticals)

Tier C — Watch / trade

Aerie Pharmaceuticals Inc

Originator

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：GR

Indications (approved)：Postoperative pain, 足底筋膜炎, Chemotherapy-induced nausea and vomiting, B-cell lymphoma, Acute lymphoblastic leukaemia, Immune thrombocytopenic purpura, Leukaemia, Hodgkin's disease

Regional status

Phase III

2022-08-23

Phase III

2022-04-01

China

Phase II

2021-08-21

Japan

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Dexamethasone intravitreal implant (Aerie Pharmaceuticals)?

Approved indications include: Postoperative pain, 足底筋膜炎, Chemotherapy-induced nausea and vomiting, B-cell lymphoma, Acute lymphoblastic leukaemia, Immune thrombocytopenic purpura, Leukaemia, Hodgkin's disease.

When does the Dexamethasone intravitreal implant (Aerie Pharmaceuticals) patent expire?

No public expiry year is available for Dexamethasone intravitreal implant (Aerie Pharmaceuticals) yet; this page updates once verified.

How do I get a quote for Dexamethasone intravitreal implant (Aerie Pharmaceuticals) intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-12